Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. - Wikidata - awgldk - TriplyDB

Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy.

Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy.

http://www.wikidata.org/entity/Q36936011

about

Molecular testing to optimize therapeutic decision making in advanced colorectal cancer Gene Expression Variations in Microsatellite Stable and Unstable Colon Cancer Cells ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy.Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy.A colorectal cancer genome-wide association study in a Spanish cohort identifies two variants associated with colorectal cancer risk at 1p33 and 8p12.ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysis.Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes Association between the ERCC1 rs11615 polymorphism and clinical outcomes of oxaliplatin-based chemotherapies in gastrointestinal cancer: a meta-analysis Translational medicine and reliability of single-nucleotide polymorphism studies: can we believe in SNP reports or not?Platinum-induced neurotoxicity and preventive strategies: past, present, and future Informative gene network for chemotherapy-induced peripheral neuropathy DNA repair gene ERCC1 C118T polymorphism predicts sensitivity of recurrent esophageal cancer to radiochemotherapy in a Chinese population.Functional Analysis of SNPs in the ERCC5 Promoter in Advanced Colorectal Cancer Patients Treated With Oxaliplatin-Based Chemotherapy GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy.Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen.Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer.Germline genetic markers for urinary bladder cancer risk, prognosis and treatment response.Biomarker-based selection of therapy for colorectal cancer.Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis.X-ray repair cross-complementing 1 polymorphism and prognosis of platinum-based chemotherapy in gastric and colorectal cancer: a meta-analysis.Personalizing colon cancer therapeutics: targeting old and new mechanisms of action.Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia.Predictive value of GSTP1 Ile105Val polymorphism in clinical outcomes of chemotherapy in gastric and colorectal cancers: a systematic review and meta-analysis.Nucleotide excision repair and response and survival to chemotherapy in colorectal cancer patients.Long-term administration and efficacy of oxaliplatin with no neurotoxicity in a patient with rectal cancer: Association between neurotoxicity and the GSTP1 polymorphism.Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients.AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin.Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer.Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration.Pharmacogenetic analysis in the treatment of Hodgkin lymphoma.Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies.Association of hOGG1 Ser326Cys, ITGA2 C807T, TNF-A -308G>A and XPD Lys751Gln polymorphisms with the survival of Malaysian NPC patients.The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients.SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand.

P2860

Q26749012-6DBB7580-462E-4E4D-9900-0E78A79F3CA5 Q29304665-BD8B3FFF-5D67-4B04-BA74-A298347B8A2E Q33634975-9EBFD463-4BF4-44CE-8460-EBF721EB0890 Q33696582-E755965C-04E0-4518-9EE0-0FE0546FE055 Q33747440-E50CF8CE-297D-4249-9598-3874CC413828 Q34008793-2738AA9F-D8EE-4911-8128-4AE2CC796DD7 Q34026282-60D3DE56-3309-462A-8133-E1FDDB8212D2 Q34563854-4136D850-F387-4C91-A57D-0351155C5787 Q34694410-DE7F8858-6EE2-4152-B0F6-117A443F00FC Q34733071-111B9542-B6FE-4975-BA9C-C69DE4879255 Q34902754-DC68FE9D-48A1-40F7-99C0-159CBF1ADA73 Q35194655-DA6620D7-7C1C-4078-ACDA-B39196A9543F Q35196724-F46CBA71-E693-4D51-B97E-464EE08D07BC Q35345734-797086CE-8A96-449A-A94E-D83C062EA05B Q35945680-2111718B-FF13-44BB-8C36-F088026CEC46 Q36247880-DF31B924-2AB8-461A-ABE9-7838A9423108 Q36993563-6CDF33F6-1B43-468D-9585-CD8897A04933 Q37206438-1540186B-12B1-4776-B39C-61BE125DC822 Q37345347-09AAE373-AF2A-4FFC-A65E-5D446FD4AC50 Q37383249-7BA50EDF-5C89-4E96-A094-7FE53D623A9D Q37468876-CBA21DD3-B7B3-4632-AF6E-E5F5430F521D Q37797468-730D4BAC-99A0-4318-BC01-304EB3354285 Q37886995-2BD31C0B-8EE9-4ABC-96E4-32CC8791C5A1 Q37887337-7AB3A98D-DE35-454D-878C-39592EB6F217 Q38072637-F9245975-5B80-4056-9162-B3595D28D43D Q38162285-184E2F22-347A-4AFA-A09F-37BECDEBBA27 Q38166233-B37DACF2-22A9-4B46-9438-F2A3957968DE Q38460343-6855F494-0593-4ABD-9D51-DAE2171A3277 Q38827826-6023EF7D-0334-4952-AC06-7B73DB63B8E1 Q38835268-D8FDC20E-9581-41E7-8CE5-FEF9533769C8 Q38932560-B842D08E-B17C-44B3-A07C-2BAAC6013D2F Q39566084-B31E4C67-2793-4B17-BB13-B1B78A0A423B Q41495258-27ADBE13-05AC-4D81-8C5C-2B9C2B6F4BE6 Q42837601-063E873E-323F-4592-BA0F-31399F15AB8A Q43986380-9E9C5793-9624-41B2-861F-CB53261489E3 Q53117544-F101AAC3-B656-459C-B01D-D62997B61A3C Q53621686-2846C461-AE19-46B3-AE05-9542FED52467 Q55249241-ECDBFC0D-2213-417E-8116-09694B837EFF Q55455554-A9675F18-1D33-439E-86BE-DA146364A689 Q55497899-D7D9720B-65BE-4D6D-ADAE-D782F36A5562

P2860

Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy.

http://www.wikidata.org/entity/Q36936011

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Pharmacogenetic prediction of ...... il as first-line chemotherapy.

@en

type

label

Pharmacogenetic prediction of ...... il as first-line chemotherapy.

@en

prefLabel

Pharmacogenetic prediction of ...... il as first-line chemotherapy.

@en

P1433

Q36936011-7F5B9BED-4917-47A1-84F0-2086EE2A3B82

P1476

Q36936011-97A9491C-EA9C-4A24-9729-BE36533698BC

P2093

Q36936011-11C452B5-D76F-4A89-9171-F183DD96A8E4

Q36936011-317E571A-FDD9-4F34-ACC5-192755ADA15E

Q36936011-6EF098CF-D74D-443E-90CD-455BEB44B4D9

Q36936011-95197592-1439-46D2-AC31-937A461A7E59

Q36936011-B0DD6A5C-9F02-4D9C-BF11-0264C3D0309D

Q36936011-E4DE79CA-386F-4866-B596-90CD9EC03E0D

Q36936011-ED55CDBA-7DB6-4E26-8F70-55F6471D700B

Q36936011-FE008ABB-1365-4F4B-ABB3-D019EF51CFE6

Q36936011-FF5A9FC5-C6B3-465A-A846-7B69FA3EE523

P2860

Q36936011-07F764E8-9A06-45D6-A5E6-0F8212E72D45

Q36936011-0D57CDD4-5213-407B-A0EB-F1D48577C066

Q36936011-1C02A420-66BF-4E25-A663-23252CC96598

Q36936011-1E9C1E75-74D8-4923-B346-3044533B30E3

Q36936011-33498F62-E5B9-49E9-AD60-1A295DCA09C8

Q36936011-376B0E05-9DCF-4110-A1FF-4213D23A835F

Q36936011-37DB1043-8C64-4AFE-8CD9-5D61FE4A5D5B

Q36936011-4C18EE79-AA83-426F-951B-2AF12753235F

Q36936011-5F4C3ED0-E266-4E18-BBD8-2E762FC31910

Q36936011-635158FF-5BDD-48A9-A13E-752C5E80E3C0

P2888

Q36936011-1855CB20-6D6C-4B51-B0AF-4BB75D3B1A8F

P304

Q36936011-86342EE3-5078-493E-BBB3-9E186E74B143

P31

Q36936011-7EF29B8F-4661-4AF2-8EC1-37058ABBC70A

P356

Q36936011-272119F9-3D4D-4556-89A9-13828B8487B4

P407

Q36936011-C64755F6-EBC5-4666-8EC5-63BC13418ACD

P433

Q36936011-1741C727-E794-4380-A259-430E2B49235E

P478

Q36936011-16501934-0085-43D1-A4B3-A4D2B3B8DF88

P577

Q36936011-F59D82B7-81AC-4C0D-8AD5-A3C2330F590F

P5875

Q36936011-54401F6A-FAFE-48EE-85F7-5CAF1075F6EF

P698

Q36936011-5306ECE1-BEB8-495F-B552-5715122EEC7E

P921

Q36936011-7F5C7E8C-8419-4699-B22B-551A5DA606E8

Q36936011-8FB5A9E6-2661-4AF0-9B3E-AB964A83C677

P932

Q36936011-997BD880-4229-4593-9E94-3A3DE3244324

P356

P1433

British Journal of Cancer

P1476

Pharmacogenetic prediction of ...... il as first-line chemotherapy.

@en

P2093

A Altés

http://www.w3.org/2001/XMLSchema#string

A Barnadas

http://www.w3.org/2001/XMLSchema#string

A Cortés

http://www.w3.org/2001/XMLSchema#string

E Marcuello

http://www.w3.org/2001/XMLSchema#string

E del Río

http://www.w3.org/2001/XMLSchema#string

J Salazar

http://www.w3.org/2001/XMLSchema#string

L Paré

http://www.w3.org/2001/XMLSchema#string

L Sedano

http://www.w3.org/2001/XMLSchema#string

M Baiget

http://www.w3.org/2001/XMLSchema#string

P2860

A simple salting out procedure for extracting DNA from human nucleated cells

LDA--a java-based linkage disequilibrium analyzer.

A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.

A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues.

Monitoring base excision repair by in vitro assays.

Management of advanced colorectal cancer: state of the art.

ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.

Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors.

Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.

Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate.

P2888

P304

1050-1055

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6604671

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P577

2008-09-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23261150

http://www.w3.org/2001/XMLSchema#string

P698

18797464

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

2567080

http://www.w3.org/2001/XMLSchema#string